# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial ...
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ: ORGO) with a Buy and maintains $7 price target.
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...
CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc.
Cantor Fitzgerald analyst Ross Osborn maintains Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and raises the price ...
Organogenesis Holdings (NASDAQ:ORGO) narrows FY2025 sales outlook from $480.00 million-$535.00 million to $480.00 million-$510....
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of...